{"nctId":"NCT01414608","briefTitle":"Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer","startDateStruct":{"date":"2012-01-09","type":"ACTUAL"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Stage IB Cervical Cancer AJCC v6 and v7","Stage IIA Cervical Cancer AJCC v7","Stage IIB Cervical Cancer AJCC v6 and v7","Stage IIIB Cervical Cancer AJCC v6 and v7","Stage IVA Cervical Cancer AJCC v6 and v7"],"count":926,"armGroups":[{"label":"Arm I (cisplatin, radiation therapy, brachytherapy)","type":"EXPERIMENTAL","interventionNames":["Radiation: Brachytherapy","Drug: Cisplatin","Radiation: External Beam Radiation Therapy","Other: Quality-of-Life Assessment"]},{"label":"Arm II (cisplatin, radiation therapy, brachytherapy, chemo)","type":"EXPERIMENTAL","interventionNames":["Radiation: Brachytherapy","Drug: Carboplatin","Drug: Cisplatin","Radiation: External Beam Radiation Therapy","Drug: Paclitaxel","Other: Quality-of-Life Assessment"]}],"interventions":[{"name":"Brachytherapy","otherNames":["Brachytherapy, NOS","Internal Radiation","Internal Radiation Brachytherapy","Internal Radiation Therapy","Radiation Brachytherapy","Radiation, Internal"]},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"]},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone''s Chloride","Peyrone''s Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"External Beam Radiation Therapy","otherNames":["Definitive Radiation Therapy","EBRT","External Beam Radiation","External Beam Radiotherapy","External Beam RT","external radiation","External Radiation Therapy","external-beam radiation","Radiation, External Beam"]},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eligible patients will have locally advanced cervical cancer suitable for primary treatment with chemoradiation with curative intent, in addition to:\n\n  * Federation of Gynecology and Obstetrics (FIGO) 2008 stage IB1 \\& node positive, IB2, IIA, IIB, IIIB, or IVA disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix\n* White blood cells (WBC) \\>= 3.0 x 10\\^9/L\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9/L\n* Platelet count \\>= 100 x 10\\^9/L\n* Bilirubin =\\< 1.5 times upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\\< 2.5 x ULN (if both tests are done, both results need to be =\\< 2.5 x ULN)\n* Creatinine =\\< ULN (Common Toxicity Criteria \\[CTC\\] grade 0) OR calculated creatinine clearance (Cockcroft-Gault formula) \\>= 60 mL/min OR \\>= 50 mL/min by ethylenediaminetetraacetic acid (EDTA) creatinine clearance\n* Written informed consent\n\nExclusion Criteria:\n\n* Any previous pelvic radiotherapy\n* Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive, or \\>= 15 mm short-axis diameter on computed tomography \\[CT\\])\n* FIGO 2008 stage IIIA disease\n* Patients assessed at presentation as requiring interstitial brachytherapy treatment\n* Patients with bilateral hydronephrosis unless at least one side has been stented and renal function fulfills the required inclusion criteria\n* Previous chemotherapy for this tumor\n* Evidence of distant metastases\n* Prior diagnosis of Crohn's disease or ulcerative colitis\n* Peripheral neuropathy \\>= grade 2 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\] version \\[v\\]4)\n* Patients who have undergone a previous hysterectomy or will have a hysterectomy as part of their initial cervical cancer therapy; this includes patients with a prior history of supracervical hysterectomy\n* Patients with other invasive malignancies, with the exception of non-melanoma skin cancer and in situ melanoma, who had (or have) any evidence of the other cancer present within the last 5 years\n* Patients who are pregnant or lactating\n* Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy\n* Serious illness or medical condition that precludes the safe administration of the trial treatment including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients who are known to be human immunodeficiency virus (HIV) positive","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival Rate at 5 Years","description":"Estimate for probability of overall survival at 5 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Rate at 5 Years","description":"Estimate for probability of progression free at 5 years by Kaplan-Meier method, where progression-free survival is defined as the time from randomization to the time of disease progression, death from any cause or date of last contact, whichever occurs first. Disease progression is defined by increasing clinical, radiological or pathological evidence of disease from participant entry to when investigator deems a progression. RECIST V1.0 was not used to determine response on this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (Grade 3 or Higher) in First Year","description":"Number of participants with a maximum grade of 3 or higher for pre-specified adverse events that occurred during the first year after randomization. Adverse events are graded and categorized using CTCAE v4.0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Patterns of Disease Recurrence","description":"Number of patients for the site of disease recurrence. Disease was considered as persistent if participant had evidence of disease at study entry and disease did not progress during study. Disease status was considered locoregional alone if a participant had disease progression in the pelvis region including vagina after study entry. Disease status was considered distant if a participant had disease progression outside the pelvis (for example the abdomen and lung) after study entry. Criteria used to determine the no progression group includes participants that expired without documentation of progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"304","spread":null},{"groupId":"OG001","value":"332","spread":null}]}]}]},{"type":"SECONDARY","title":"Radiation Protocol Compliance","description":"Radiation protocol compliance measured by external beam dose delivered","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null},{"groupId":"OG001","value":"45.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life for Global Health Status","description":"Quality of Life measured by change of global health status score from baseline to 12 months follow-up. A cancer-specific questionnaire with 30 items which summarize as five functioning scales, a global health status/quality of life scale, three symptom scales and six single items assessing additional symptoms and perceived financial impact. The minimum global health status score was 0 and the maximum global health status score was 100. A higher global health status score means better outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"22.8"},{"groupId":"OG001","value":"2.4","spread":"26.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":453},"commonTop":["Fatigue","Nausea","Diarrhea","Lymphocyte count decreased","Anemia"]}}}